Research
Independent equity research and analytical deep-dives.
- Targeted Protein Degradation: Comparative Clinical Milestones of Mezigdomide and Cemsidomide
An objective review of recent clinical data for Bristol Myers Squibb's mezigdomide and C4 Therapeutics' cemsidomide in relapsed/refractory multiple myeloma, evaluating efficacy metrics, safety profiles, and developmental progress.
- Metabolic Disruption: Comparative Mechanistic Positioning of Pemvidutide and Icovamenib
An objective evaluation of alternative clinical paradigms in metabolic disease, comparing Altimmune’s GLP-1R/GCGR dual agonist pemvidutide with Biomea Fusion’s glucose-responsive menin inhibitor icovamenib.
- Targeted Radiopharmaceuticals: Comparative Clinical Milestones of 177Lu-RAD202 and Iomab-B
An objective review of recent clinical data for Radiopharm Theranostics' 177Lu-RAD202 and Actinium Pharmaceuticals' Iomab-B, evaluating efficacy metrics, safety profiles, and developmental progress.